Clinical Trials
3 trialsNCT03916627 2026-04-06
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT06923761 2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2 Recruiting
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown